Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0017636 (glioblastoma)
 18,345 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Three cases of glioblastoma multiforme are described, occurring in two brothers and the sister of their father. One of the cases was found at autopsy to represent true multicentric glioblastoma, with five widely separated lesions affecting both hemispheres. It is postulated that there may be an association between factors responsible for multiple foci of transformation and a familial tendency to develop glioma.
 ...
PMID:Glioblastoma multiforme in three family members, including a case of true multicentricity. 301 72

In surgical specimens of 91 cases of malignant glial tumor, the correlation between the clinical malignancy of the tumors and the presence of GFA protein in the surgical specimen was examined. In anaplastic astrocytomas, 20 of 27 cases revealed positive staining of GFAP. In the cases of glioblastoma multiforme 27 of 35 cases showed GFAP positive staining. On the other hand, in medulloblastomas, all 29 cases were negative. In anaplastic astrocytomas and glioblastoma multiforms, the difference between the survival curves of GFAP positive groups and negative groups were examined. Between two groups, there was no statistical differences. In this study, the presence of GFAP was not proportional to the degree of tumor differentiation, and the GFAP staining of the tumor tissue was not a valuable examination showing the prognosis of the patient.
 ...
PMID:[Clinicopathological study on malignant glioma--with special reference to GFAP]. 302 Apr 63

The Neuro-oncology Service of the University of California Brain Tumor Research Center conducted a nonrandomized phase II study to evaluate, in patients with recurrent malignant glioma, the benefit of a four-drug combination (BFHM) consisting of carmustine (1,3-bis (2-chloroethyl)-1-nitrosourea), 5-fluorouracil, hydroxyurea, and 6-mercaptopurine. There were 29 evaluable glioblastoma multiforme patients and 45 nonglioblastoma anaplastic glioma patients available for analysis. Tumor progression was analyzed as the primary study endpoint. Of the glioblastoma patients, 16 of 29 (55%) responded or stabilized on therapy; of the other anaplastic gliomas, 32 of 45 (71%) responded or stabilized. For patients who stabilized or responded to treatment, BFHM achieved a median time to tumor progression of 46 weeks with a 25th percentile time to tumor progression of 68 weeks for anaplastic gliomas and a median time to tumor progression of 23 weeks with a 25th percentile time to tumor progression of 36 weeks for glioblastoma multiforme patients. A Cox multivariate analysis demonstrated that age and Karnofsky score were important prognostic variables for these patients.
 ...
PMID:Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas. 302 25

The purpose of this study is to present the methodology and results of a clinical trial of local chemotherapy of malignant brain tumors based on slowly-releasing anticancer drug-polymer composites. The slowly releasing drugs were prepared by combining and mutually dispersing anticancer agents with glassified monomers containing 10% polymetacrylic methyl acid and then this compound was frozen at -78 degrees C and exposed to 1 X 10(6) rad of gamma rays from cobalt 60. Thus we prepared a compound of polymers and anticancer agents. We used needle-shaped capsules of this compound. These capsules release the drug very slowly over 40 days. We administered locally to the malignant brain tumors with either slowly releasing mitomycin, slowly releasing adriamycin, slowly releasing ACNU or slowly releasing 5 Fu drugs. The following techniques were employed in implantation these capsules. Implantation into the remaining tumor wall at the time of excision. Implantation into the tumor by CT-guided stereotactic method. We implanted these drugs into tumor of 55 cases, thereafter we conducted both radiation and chemotherapy with ACNU in most patients. This method has the following advantages: It is possible to be employed to different types of anticancer agents. Both dosage and releasing time can be adjusted. It is possible to administer these capsules postoperatively by the stereotactic method. The clinical study consists of 55 patients, 20 cases of anaplastic astrocytoma, 23 cases of glioblastoma multiforme, 5 cases of oligodendroglioma, 3 cases of medulloblastoma and 4 cases of others. Survival rate estimated by Kaplan-Meier method was 47% in glioblastoma at 12 months and 91% in anaplastic astrocytoma at 18 months.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Treatment of malignant brain tumors with slowly releasing anticancer drug-polymer composites]. 302 49

Histologic sections from 71 patients with glioblastoma multiforme were reviewed to identify histologic prognostic factors and to explain the significantly shorter survival in older patients. Slides were studied for 14 histologic variables from a group of 35 patients aged less 45 years and from 36 patients aged 65 years or more. The relation of these histologic factors to the length of survival and age group was then investigated. The results document the marked histologic and cytologic heterogeneity of the glioblastoma and reaffirm the importance of necrosis as a prognostic factor. The results further suggest that patients whose glioblastomas contained microcysts, pseudopalisading, cells with astrocytic differentiation, and large areas of better differentiated glioma, did better than those patients whose lesions were homogeneously composed of small cells or whose lesion had a small median nuclear size. The study reaffirmed the strong (P less than 0.0001) negative relationship between advancing age and duration of postoperative survival. The presence of necrosis, a smaller standard deviation of nuclear size, the extent of vascular proliferation, the absence of well differentiated neoplastic fibrillary astrocytes, and neoplasms composed homogeneously of small cells were related to patient age and offered a possible explanation for at least part of the observed age effect. However, the strong relation between age and survival remained significant when adjusted for other variables, and the effect of age must rest largely on factors other than those detected in this morphologic study.
 ...
PMID:Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. 303 May 31

Precise localization of alkaline phosphatase (ALPase) activity in human gliomas was examined by light and electron microscopy in association with malignant transformation, paying much attention to changes in blood-brain barrier. Materials used were eight cases of gliomas four of which were astrocytoma grade 2, one astrocytoma grade 3, and three, glioblastoma multiforme, respectively. Specimens were quickly fixed in cacodylate-buffered 2% glutaraldehyde at 4 degrees C for 1 hour and rinsed overnight in the same buffer. Frozen or nonfrozen sections (40 microns thick) were made and incubated at 20 degrees C for 40 min, and processed for light and electron microscopy. For the demonstration of ALPase activity, the lead citrate method (Mayahara et al., 1967) was employed. By light microscopy, ALPase activity appeared to be mainly restricted to the capillary wall. By electron microscopy, reaction product representing ALPase activity was distributed in the plasma membrane of endothelial cells both in astrocytomas and in glioblastoma. In astrocytoma grade 2, activity was primarily localized along the abluminal surface of endothelial cells. In glioblastoma, on the other hand, ALPase activity was positive on the luminal surface of the plasma membrane of endothelial cells. It was much more intense than that along the abluminal surface. Regional differences in enzyme cytochemistry may represent functional heterogeneity in the endothelial cell membrane. In brain tumors, changes in distribution pattern of enzyme activity were visualized in the present study in association with glioma malignancy. This might represent a functional aspect of changes in blood-brain barrier in human glioma tissue during course of its malignant transformation.
 ...
PMID:[Alkaline phosphatase activity in human gliomas as revealed by light and electron microscopy]. 304 56

This study was undertaken to determine the maximum tolerated dose of aziridinylbenzoquinone (AZQ) given as a 24-hour intravenous infusion every 21-28 days. Thirty-four patients with recurrent or progressive gliomas received AZQ at a dose of 25, 30, 35, 40, or 45 mg/m2. At a dose of 45 mg/m2, leukopenia and thrombocytopenia of grade 3 or greater was observed in 42% and 25% of patients respectively; no patient required transfusion or antibiotics for fever. For administration of AZQ at a 24-hour intravenous infusion, we recommend a starting dose of 40 mg/m2 for patients without previous exposure to cytotoxic agents, and 35 mg/m2 for patients treated with such agents. In 14 patients with glioblastoma, tumor regression was observed in 1 patient (14%) and stabilization of disease was demonstrated in 7 patients (50%). In 17 patients with anaplastic astrocytomas there were no responses, but 8 patients (47%) stabilized. Of two patients with an oligodendroglioma, one continues without progression at 34 weeks after initial response. One patient with malignant ependymoma stabilized and had not progressed at 39 weeks. The median time to tumor progression in patients who stabilized and responded was 18 weeks for those with glioblastoma multiforme and 16 weeks in those with anaplastic astrocytomas.
 ...
PMID:A phase I/II study of 24 hour intravenous AZQ in recurrent primary brain tumors. 322 Dec 59

On the surgery of glioblastoma multiforme, most cases are beyond the scope for desirable removal of tumors. The restriction of the surgical treatment has inevitably required postoperative radiation therapy. Although patients treated with postoperative radiation therapy showed significantly extended survival rates as compared to those receiving surgical resection alone, the glioblastoma recurred within a 2cm margin of the primary site in more than 90% of the patients and conventional external radiation therapy with a doses of 50-60 Gy did not result in local cure. However, it was reported that survivals extended in proportion to target absorbed doses and suggested that a higher localized radiation dose would improve the poor prognosis of these tumors. In order to obtain a local cure of glioblastoma, the first step of therapy should be an intensive local treatment. Intraoperative radiation therapy (IOR) and brachytherapy using high activity iodine-125 or iridium-192 become a logical local treatment for sterilizing the remaining malignant remnants by a high target absorbed dose without damaging surrounding brain tissues. IOR for 19 patients with glioblastoma resulted in a 2-year survival rate of 61.4%. Brachytherapy has shown excellent local effects for recurrent tumors.
 ...
PMID:[Radiation-therapy of malignant gliomas]. 331 2

The prognostic importance of tumor size was studied in 510 patients with malignant glioma (80% with glioblastoma multiforme) in the Valid Study Group of Study 80-01 of the Brain Tumor Study Group (now the Brain Tumor Cooperative Group [BTCG]). The endpoint was length of survival from randomization, which occurred within 3 weeks of definitive surgery. Following randomization, patients were scheduled to receive radiotherapy (RT) (6,020 cGy) during a 7-week period, along with continuing courses of chemotherapy. Computed tomographic (CT) scan information was available for 124 patients preoperatively, 300 patients postoperatively (preradiation), and 218 patients 9 weeks post-RT (+/- 3 weeks). Tumor size was determined as area (length x width) on the contrast-enhanced scan and survival was compared by log rank statistics. Preoperative tumor area was unrelated to survival (P = .48), but postoperative area was significantly prognostic (P less than .0001); the smaller the residual tumor, the longer the patient lived. Patients with a 75% or greater resection, as determined by measuring the difference between the preoperative and the postoperative scans, tended to have better survival, but the difference was not significant (P = .16). The post-RT area was strongly related to survival (P less than .00001). The percent change in area between the pre- and post-RT scans was also prognostic. Tumor size was of prognostic importance independent of the other known prognostic variables: age, Karnofsky performance score, and whether the tumor was glioblastoma or anaplastic astrocytoma. We conclude that the amount of tumor remaining after surgery is an important baseline variable at the start of RT, and that the tumor size 9 weeks following RT is also prognostic. Surgical resection is most important when it leaves the least amount of residual tumor.
 ...
PMID:The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. 333 97

By using Southern blot analysis, we found that in two cases of human glioblastoma multiforme, cells carried amplified c-erbB genes which bore short deletion mutations within the ligand-binding domain of the epidermal growth factor (EGF) receptor. The products of these mutated c-erbB genes were about 30 kilodalton (kDa) smaller than the normal 170-kDa EGF receptor, and the tumor cell membrane fractions containing the 140-kDa abnormal EGF receptor showed a significant elevation of tyrosine kinase activity without its ligand. In view of the similarity to the activated viral and cellular erbB genes in the avian system, these mutated and overexpressed EGF receptors might play a role in the onset or development of human glioblastoma cells.
 ...
PMID:Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors. 338 99


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>